TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00983515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
Study: NCT01757626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu3F8 With GM-CSF
Description: Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 \& 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m\^2/day (day -4 to day 0), \& at 500 mcg/m\^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu3F8 With GM-CSF
Description: As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
Study: NCT02625961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants with CIS with or without papillary tumors (Cohort A) and participants with papillary tumors only, without CIS (Cohort B) receive pembrolizumab 200mg via IV infusion once every 3 weeks for up to 35 administrations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/vibostolimab coformulation
Description: Participants with CIS with or without papillary tumors (Cohort C) receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion once every 3 weeks for up to 35 administrations
Study: NCT03029299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilmArray RP EZ
Description: Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
Study: NCT02500147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
Study: NCT02625961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/pembrolizumab coformulation
Description: Participants with CIS with or without papillary tumors (Cohort C) receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion once every 3 weeks for up to 35 administrations
Study: NCT03362216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Methyl Salicylate Liniment
Description: Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium Liniment
Description: Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
Study: NCT03170089

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Health Educational Program
Description: Oral Hygiene methods learned
Study: NCT02975206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serlopitant High Dose
Description: serlopitant tablets - high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serlopitant Low Dose
Description: serlopitant tablets - low dose
Study: NCT00508820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
Study: NCT02263924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
Study: NCT00755521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg
Study: NCT00144456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ED-71
Description: 0.75μg/day(p.o.)for 144 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Description: 1.0μg/day(p.o.)for 144 weeks
Study: NCT03643640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimune
Description: Optimune is a web-based psychological intervention developed for women with breast cancer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care-As-Usual
Description: Participants are free to continue to engage with any treatment they require (i.e., CAU).
Study: NCT02500147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
Study: NCT00144456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ED-71 placebo
Description: 0 μg/day(p.o.)for 144 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol placebo
Description: 0 μg/day(p.o.)for 144 weeks
Study: NCT03602521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpersonal stress
Description: Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~* 1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~* 2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal stress
Description: Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~* 1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~* 2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?
Study: NCT02132169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: AC-170 0.24%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Study: NCT03702023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Intervention group will receive 1000 mg of acetaminophen
Study: NCT06699589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Old SCHOOL Hip-Hop (Dementia Education)
Description: A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: My Plate (Nutrition Education)
Description: The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program.
Study: NCT03702023

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Control group will be given a placebo capsule.
Study: NCT00888316

Intervention type: PROCEDURE
Intervention: magnetic resonance imaging
Description: MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC.

Intervention type: PROCEDURE
Intervention: magnetic resonance imaging
Description: MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC.

Intervention type: PROCEDURE
Intervention: Serum ferritin
Description: Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant

Intervention type: PROCEDURE
Intervention: Serum ferritin
Description: Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
Study: NCT00878644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Normothermia
Description: Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
Study: NCT03224936

Intervention type: DEVICE
Intervention: PSI
Description: The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
Study: NCT03109418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: OSA patients receiving standard inhaled anesthesia combined with normal saline
Study: NCT01432756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Talk Worksite Parenting Program
Description: The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
Study: NCT00722410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: A probiotic preparation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: A probiotic preparation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Description: Oral ingestion of 3 liters of polyethylene glycol solution.
Study: NCT04623268

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and questionnaire
Description: One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and questionnaire
Description: One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group
Study: NCT02068846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
Study: NCT04594265

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KetoneAid KE4 Pro Monoester
Description: A dietary supplement containing ketone monoester.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: KetoneAid KE4 Pro Monoester
Description: A dietary supplement containing ketone monoester.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Science in Sport Go Enegy
Description: Dosis isocaloric to the KetoneAid Arm
Study: NCT03258281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Patients will receive evolocumab 420 mg administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo administered subcutaneously
Study: NCT02947854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimaporfin (Photosensitizer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimaporfin (Photosensitizer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimaporfin (Photosensitizer)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiltonol (Poly-ICLC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiltonol (Poly-ICLC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiltonol (Poly-ICLC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV E7 (Human Papilloma Virus E7) peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV E7 (Human Papilloma Virus E7) peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH (Keyhole Limpet Hemocyanin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH (Keyhole Limpet Hemocyanin)
Study: NCT00803257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbrical splint and Lumbrical exercises
Description: Subjects receive one of four possible interventions - Dose and Frequency are the same for each

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbrical splint and Lumbrical exercises
Description: Subjects receive one of four possible interventions - Dose and Frequency are the same for each

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbrical splint and Lumbrical exercises
Description: Subjects receive one of four possible interventions - Dose and Frequency are the same for each

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbrical splint and Lumbrical exercises
Description: Subjects receive one of four possible interventions - Dose and Frequency are the same for each
Study: NCT00182780

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American ginseng

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT00962169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral and managerial
Description: The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral and IT
Description: The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
Study: NCT02526524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met IR
Description: metformin immediate-release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02562209

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PACER Diet
Description: Pacer diet to be followed for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard weight reducing diet
Description: Standard weight reducing diet to be followed for 8 weeks
Study: NCT01971463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: intravenous administration of 500cc of 0.9% NaCl over 30 minutes
Study: NCT03396679

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
Study: NCT04385238

Intervention type: OTHER
Intervention: This is an online survey with no intervention.
Description: As this is an online survey about health and wellbeing, there is no intervention.

Intervention type: OTHER
Intervention: This is an online survey with no intervention.
Description: As this is an online survey about health and wellbeing, there is no intervention.
Study: NCT04465435

Intervention type: OTHER
Intervention: Web-based self-report questionnaires
Description: Web-based self-report questionnaires based on well established instruments.

Intervention type: OTHER
Intervention: Focus Group Interviews
Description: Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
Study: NCT02676336

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Violet™ Molecular Iodine (I2)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Violet™ Molecular Iodine (I2)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00989521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PUR003
Description: PUR003 for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline for inhalation
Study: NCT04607941

Intervention type: OTHER
Intervention: Questionnaires
Description: Self-administered questionnaires

Intervention type: OTHER
Intervention: Questionnaires
Description: Self-administered questionnaires